$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Public Health

WHO Europe Reports Antibiotic Resistance Rising Since 2019

The World Health Organization's European office and the European Centre for Disease Prevention and Control reported on November 18, 2026, that infections from the hospital bacterium Klebsiella pneumoniae rose an estimated 72 percent between 2019 and 2025 against a target cut of 5 percent, cephalosporin resistant E. coli infections rose more than 16 percent against a target cut of 10 percent, and resistance reached at least half of samples in about one in two countries in the region.

TML Health DeskNov 19, 5:17 AM ET · 3 min read

Edited and fact-checked by Stephen Sprague

Klebsiella pneumoniae colonies on MacConkey agar (archive). Photo: Ajay Kumar Chaurasiya, CC BY-SA 4.0, via Wikimedia Commons.
Summary

Only 22 percent of countries report both funding and full implementation of their resistance plans.

Tap a passage. React to the part that matters.

A hospital patient in Europe whose first antibiotic fails now faces a measurable pattern, and the agencies tracking it published the numbers on Wednesday. The World Health Organization's European office and the European Centre for Disease Prevention and Control assessed progress between 2019 and 2025 against targets meant to shrink resistant infections. Infections from Klebsiella pneumoniae, a bacterium that thrives in healthcare settings, rose an estimated 72 percent, where the target was a 5 percent fall, and infections with E. coli resistant to cephalosporins, a standard antibiotic group, rose more than 16 percent, where the target was a 10 percent fall.

Dr. Marc-Alain Widdowson, head of health security at WHO Europe, described the clinical sequence in plain terms, and in many countries in the region, he said, "the antibiotics doctors usually reach for first are failing against serious hospital infections." When a first drug fails, doctors move to carbapenems, the stronger drugs kept for the most serious cases, and he warned about what follows that step. "When those stop working too, what's left is mostly a small group of last-resort drugs that are often expensive and not available in every country," he said. "Each time one of these lines of defence falls, patients move closer to having no good options at all. That matters, because people whose first antibiotic doesn't work against their infection are more likely to die in hospital."

Resistance to key antibiotics reached at least half of tested Klebsiella pneumoniae samples in about one in two countries in the region, and Acinetobacter, another hospital bacterium, showed the same pattern, and these are laboratory findings from surveillance networks. The agencies caution that testing and reporting differ by country, so national results are not directly comparable, and the direction is consistent across the two networks the report draws on. One network covers the European Union and European Economic Area, and one covers participating countries elsewhere in the WHO European Region, and a resistant result in the laboratory means the drug is unlikely to work against that bacterium. It does not by itself measure how any individual patient fared.

Testing capacity is part of the failure the report describes, because hospitals that take few blood samples cannot identify the bacterium behind an infection before treatment starts, and doctors in those wards have to choose an antibiotic without knowing which one will work. The WHO said that leaves health systems planning half blind, unable to tell where resistance is spreading, and of 51 countries analysed in the agency's wider work, 16 still lack a standardized national approach and national coordination. The global survey published the same week found 173 of 183 responding countries now have national antimicrobial resistance plans, and only 22 percent report both the funding and the full implementation those plans require.

One line in the European assessment moved the other way, because the estimated rate of bloodstream infections from resistant Acinetobacter has almost halved since its peak in 2021, during the COVID-19 pandemic, and the agencies released the findings during World AMR Awareness Week. The week runs November 18 to 24 under the theme "One Health, one action: Prevent AMR now," and for patients the practical meaning sits in the first prescription. A first drug that works is the difference the whole system is organized around, and the 2019 to 2025 record shows that difference getting harder to deliver in the region's hospitals.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.